Effect of Inhibition of the Renin-Angiotensin System on Development of Type 2 Diabetes Mellitus (Meta-Analysis of Randomized Trials)
Authors:
- David L. BrownDBDavid L. Brown
- 1 April 2007
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 99 (7) , 1006-1012
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialThe Lancet, 2005
- Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 DiabetesJACC, 2005
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 studyThe Lancet, 1999
- Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialThe Lancet, 1999
- Renoprotection and Renin-Angiotensin System Blockade in Diabetes MellitusAmerican Journal of Hypertension, 1997
- Selecting and Appraising Studies for a Systematic ReviewAnnals of Internal Medicine, 1997
- Empirical Evidence of BiasJAMA, 1995
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993